Publication Date
9-1-2022
Journal
Annals of Internal Medicine
DOI
10.7326/M22-1503
PMID
35939810
PMCID
PMC9384272
PubMedCentral® Posted Date
8-9-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
no
Keywords
Adult, Designed Ankyrin Repeat Proteins, Double-Blind Method, Humans, Recombinant Fusion Proteins, SARS-CoV-2, Treatment Outcome, COVID-19 Drug Treatment
Abstract
BACKGROUND: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection.
OBJECTIVE: To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone.
DESIGN: Double-blind, randomized, placebo-controlled, clinical trial. (ClinicalTrials.gov: NCT04501978).
SETTING: Multinational, multicenter trial.
PARTICIPANTS: Adults hospitalized with COVID-19.
INTERVENTION: Intravenous ensovibep, 600 mg, or placebo.
MEASUREMENTS: Ensovibep was assessed for early futility on the basis of pulmonary ordinal scores at day 5. The primary outcome was time to sustained recovery through day 90, defined as 14 consecutive days at home or place of usual residence after hospital discharge. A composite safety outcome that included death, serious adverse events, end-organ disease, and serious infections was assessed through day 90.
RESULTS: An independent data and safety monitoring board recommended that enrollment be halted for early futility after 485 patients were randomly assigned and received an infusion of ensovibep (
LIMITATION: The trial was prematurely stopped because of futility, limiting power for the primary outcome.
CONCLUSION: Compared with placebo, ensovibep did not improve clinical outcomes for hospitalized participants with COVID-19 receiving standard care, including remdesivir; no safety concerns were identified.
PRIMARY FUNDING SOURCE: National Institutes of Health.
Included in
Clinical Epidemiology Commons, COVID-19 Commons, Internal Medicine Commons, Medical Sciences Commons